This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MOUNTAIN VIEW, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) --
Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure
® procedure, the leading non-surgical permanent birth control method, today announced that the Company will release 2012 third quarter financial results on Tuesday, October 23, 2012, after the close of market. Management will host an investment community conference call beginning at 4:30 p.m. Eastern time on October 23, 2012, to discuss the results and answer questions.
Conference call dial-in information is as follows:
U.S. callers: (888) 803-8296
International callers: (706) 634-1250
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website,
A telephone replay will be available from 6:30 p.m. Eastern time on October 23, 2012, through 11:59 p.m. Eastern time on October 26, 2012. Replay dial-in information is as follows:
U.S. callers: (855) 859-2056
International callers: (404) 537-3406
Conference ID number (U.S. and international): 37317359
About the Essure ® Procedure
The Essure procedure, FDA approved since 2002, is the only surgery-free and hormone-free permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body works with the inserts to form a natural barrier in the fallopian tubes to prevent sperm from reaching the egg. Three months after the Essure procedure, an Essure Confirmation Test is given to confirm that the inserts are in place and that the fallopian tubes are blocked, verifying that the patient can rely on Essure for permanent birth control.